<DOC>
	<DOCNO>NCT00723554</DOCNO>
	<brief_summary>A Phase IIIb , Multicenter , Open-Label Study Patients With Pulmonary Arterial Hypertension Treated With Iloprost ( Inhalation ) Evaluating Safety Inhalation Times When Converting From Power Disc-6 Power Disc-15 With I-neb® Adaptive Aerosol Delivery® System ( I-neb® AAD® )</brief_summary>
	<brief_title>Iloprost Power Disc-15 Pulmonary Arterial Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Iloprost</mesh_term>
	<criteria>Signed informed consent prior initiation studymandated procedure . Male female patient age 1885 year . Patients symptomatic pulmonary arterial hypertension New York Heart Association ( NYHA ) functional class III IV time initiation iloprost inhalation ( Ventavis® ) therapy use Power Disc6 ( PD6 ) . Patients follow type pulmonary arterial hypertension ( PAH ) belong World Health Organization ( WHO ) Group I : 1.1 : Idiopathic ( IPAH ) 1.2 : Familial ( FPAH ) 1.3 : Associated ( APAH ) 1.3.1 : Collagen vascular disease 1.3.2 : Congenital systemictopulmonary shunt least 2 year post surgical repair 1.3.4 : Human immunodeficiency virus ( HIV ) infection 1.3.5 : Drugs toxins PAH confirm recent right heart catheterization showing : Mean pulmonary arterial pressure ( mPAP ) ≥ 25 mmHg rest Pulmonary capillary wedge pressure ( PCWP ) ≤ 15 mmHg leave ventricular end diastolic pressure ( LVEDP ) ≤ 15 mmHg . If PCWP LVEDP available LVEDP value retain inclusion . Pulmonary vascular resistance ( PVR ) &gt; 240 dynsec/cm^5 Compliant treatment regimen commercial iloprost inhalation ( Ventavis® 5 μg ) use Ineb® AAD® equip PD6 least 4 week prior screen . Pulmonary function test ( PFTs ) include force vital capacity ( FVC ) , forced expiratory volume 1 second ( FEV1 ) , total lung capacity ( TLC ) , perform within 6 month screen . If take medication PAH , must stable 60 day prior baseline . If taking corticosteroid , must stable 60 day prior baseline . Women childbearing potential negative urine pretreatment pregnancy test baseline : consistently correctly use ( screen 28 day discontinuation study drug ) reliable method contraception Pearl index &lt; 1 % , sexually abstinent , vasectomized partner . A woman consider childbearing potential unless meet least one follow criterion : Previous bilateral salpingooophorectomy hysterectomy Premature ovarian failure confirm specialist gynecologist XY genotype , Turner syndrome , uterine agenesis Is age &gt; 50 year treat kind hormone replacement therapy ( HRT ) least 2 year prior screen , amenorrhea least 24 consecutive month PAH belonging WHO group IIV . PAH belong WHO group I list inclusion criterion , i.e. , PAH associate : 1.3.3 : Portal hypertension 1.3.6 : Other ( thyroid disorder , glycogen storage disease , Gaucher disease , hereditary hemorrhagic telangiectasia , hemoglobinopathy , myeloproliferative disorder , splenectomy ) 1.4 : Associated significant venous capillary involvement : 1.4.1 : Pulmonary venoocclusive disease ( PVOD ) 1.4.2 : Pulmonary capillary hemangiomatosis ( PCH ) . Receipt prostacyclin prostacyclin analog iloprost within 12 week screen . Anticipation need intravenous prostacyclin use within 28 day start Power Disc15 ( PD15 ) . HIVseropositive following : Concomitant active opportunistic infection within 6 month prior screen Detectable viral load within 6 month screen CD4+ Tcell count &lt; 200 mm^3 within 3 month screen Changes antiretroviral regimen within 3 month screen Anticipated change antiretroviral regimen study period 1 2 Using inhaled pentamidine Systemic hypotension systolic blood pressure &lt; 95 mmHg . Uncontrolled systemic hypertension ( systolic blood pressure &gt; 160 mmHg diastolic blood pressure &gt; 100 mmHg repeat measurement ) . History leftsided heart disease , include follow : hemodynamically significant aortic mitral valve disease restrictive congestive cardiomyopathy leave ventricular ejection fraction &lt; 40 % multigated radionucleotide angiogram ( MUGA ) , angiography , echocardiography coronary artery disease continue symptom angina pectoris lifethreatening cardiac arrhythmia Atrial septostomy within 1 year . History pulmonary embolism prior diagnosis PAH unless document chronic thromboembolic pulmonary hypertension ( CTEPH ) specifically exclude ( e.g. , ventilation/perfusion ( VQ ) scan , pulmonary angiogram ) . Restrictive lung disease : TLC &lt; 60 % normal predict value . Obstructive lung disease : forced expiratory volume/forced vital capacity ( FEV1/FVC ) &lt; 0.5 clinically relevant chronic obstructive lung disease asthma ( include patient require concomitant medication control symptom bronchospasm include need ( p.r.n . ) use ) . Clinically relevant bleeding disorder active bleeding . Moderate severe hepatic impairment , i.e. , ChildPugh Class B C hepatic cirrhosis . Pregnant breastfeeding . Chronic renal insufficiency , define creatinine &gt; 2.5 mg/dL requirement dialysis . Hemoglobin &lt; 75 % low limit normal range . Any condition prevents compliance protocol adherence therapy ability provide inform consent . Participation clinical trial , except observational , receipt investigational product within 30 day prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>pulmonary arterial hypertension</keyword>
	<keyword>inhale therapy</keyword>
	<keyword>power disc-15</keyword>
</DOC>